Department of Oral and Maxillofacial Surgery, Section of Dentistry, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam, 13620, Korea.
Department of Oral and Maxillofacial Surgery, Armed Forces Capital Dental Hospital, Armed Forces Medical Command, Seongnam, Korea.
BMC Oral Health. 2022 Mar 29;22(1):97. doi: 10.1186/s12903-022-02142-0.
This study was performed to evaluate the long-term clinical efficacy of the CA implants (Osstem Implant, Busan, Korea), calcium-modified surfaced treated implants on acid-etched surfaces sandblasted with alumina.
From January 2013 to December 2015, 258 implants of 120 patients placed between 2013 and 2015 were retrospectively studied. Using medical records and periapical radiographs, sex, age, location, fixture width and length of placed implants, presence or absence of bone graft, types of bone substitutes and membrane used for bone grafting, primary and secondary stability, initial and delayed complications, and marginal bone loss were investigated. The success rate and survival rate of the implants in each group were analyzed retrospectively based on the criteria suggested by Albrektsson et al. RESULTS: Between 2013 and 2015, with a follow-up longer than 5 years, 258 implants with an average diameter of 4.63 mm (3.5-5.5 mm) and an average length of 9.94 mm (7.0-13.0 mm) were placed in a total of 120 patients (61 males and 59 females) with a mean age of 63.7 years for an average of 62 months of observation period. The survival rate was 97.3%, the success rate was 94.2%, and the average final marginal bone loss was 0.074 mm.
The CA implants manufactured with the improved surface treatment method exhibited a survival rate of 97.3% and a success rate of 94.2% over an average observation period of 62 months. The implants were not affected by most factors and had very high survival and success rates over a long period of observation. In particular, the stability of the implant was excellent, with no cases of failed implants in delayed placement after bone grafting and a healing period.
本研究旨在评估 CA 种植体（Osstem Implant，韩国釜山）的长期临床疗效，该种植体为经酸蚀处理的钙改性表面喷砂氧化铝处理种植体。
回顾性研究了 2013 年 1 月至 2015 年 12 月期间 120 名患者的 258 枚种植体。通过病历和根尖片，调查了植入物的性别、年龄、部位、植入物的固定器宽度和长度、是否存在骨移植、使用的骨替代物和移植膜的类型、初次和延迟并发症、以及边缘骨吸收情况。根据 Albrektsson 等人提出的标准，分析了每个组中种植体的成功率和存活率。
2013 年至 2015 年间，对 258 枚种植体进行了随访，随访时间超过 5 年，平均直径为 4.63mm（3.5-5.5mm），平均长度为 9.94mm（7.0-13.0mm），共植入 120 名患者（61 名男性和 59 名女性），平均年龄为 63.7 岁，平均观察期为 62 个月。存活率为 97.3%，成功率为 94.2%，最终平均边缘骨吸收量为 0.074mm。
采用改进表面处理方法制造的 CA 种植体在平均 62 个月的观察期内，存活率为 97.3%，成功率为 94.2%。该种植体不受大多数因素影响，在长期观察中具有非常高的存活率和成功率。特别是，种植体的稳定性非常好，在骨移植和愈合期后延迟放置的情况下，没有种植体失败的病例。
